Potential drug–drug interactions in Alzheimer patients with behavioral symptoms

References

• BuxtonILBenetLZPharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and EliminationBruntonLLChabnerBAKnollmannBCGoodman & Gilman’s The Pharmacological Basis of Therapeutic12th edNew YorkMcGraw-Hill2011
   Google Scholar
• MalletLSpinewineAHuangAThe challenge of managing drug interactions in elderly peopleLancet2007370958218519117630042
   PubMed Web of Science ®Google Scholar
• HanlonJTLindbladCIHajjarERMcCarthyTCUpdate on drug-related problems in the elderlyAm J Geriatr Pharmacother200311384315555464
   PubMedGoogle Scholar
• GurwitzJHFieldTSHarroldLRIncidence and preventability of adverse events among older persons in the ambulatory settingJAMA200328991107111612622580
   PubMed Web of Science ®Google Scholar
• TangiisuranBWrightJVan der CammenTRajkumarCAdverse drug reactions in elderly: challenges in identification and improving preventative strategiesAge Ageing200938435835919420141
   PubMed Web of Science ®Google Scholar
• SeeleyWWMillerBLDementiaLongoDLFauciASKasperDLHauserSHJamesonJLLoscalzoJHarrison’s Principles of Internal Medicine18th edNew YorkMcGraw-Hill2012
   Google Scholar
• LyketsosCGSteinbergMTschanzJTMental and behavioral disturbances in dementia: indings from the Cache County Study on Memory in AgingAm J Psychiatry2000157570871410784462
   PubMed Web of Science ®Google Scholar
• RopackiSAJesteDVEpidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003Am J Psychiatry2005162112022203016263838
   PubMed Web of Science ®Google Scholar
• LópezOLZivkovicGSmithGBeckerJTMeltzerCCDeKoskySTPsychiatric symptoms associated with cortical-subcortical dysfunction in Alzheimer’s diseaseJ Neuropsychiatry Clin Neurosci2001131566011207330
   PubMed Web of Science ®Google Scholar
• AndersenFViitanenMHalvorsenDSStraumeBEngstadTACo-morbidity and drug treatment in Alzheimer’s disease. A cross sectional study of participants in the dementia study in northern NorwayBMC Geriatr2011115821970467
   PubMed Web of Science ®Google Scholar
• HeunRSchoepfDPotluriRNatalwalaAAlzheimer’s disease and co-morbidity: increased prevalence and possible risk factors of excess mortality in a naturalistic 7-year follow-upEur Psychiatry2013281404821924588
   PubMed Web of Science ®Google Scholar
• SmallGWRabinsPVBarryPPDiagnosis and treatment of Alzheimer’s disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics SocietyJAMA199727816136313719343469
   PubMed Web of Science ®Google Scholar
• BraunerDJMuirJCSachsGATreating nondementia illnesses in patients with dementiaJAMA2000283243230323510866871
   PubMed Web of Science ®Google Scholar
• O’BrienJTBurnsABAP Dementia Consensus GroupClinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for PsychopharmacologyJ Psychopharmacol2011258997101921088041
   PubMed Web of Science ®Google Scholar
• GironMSForsellYBernstenCThorslundMWinbladBFastbomJPsychotropic drug use in elderly people with and without dementiaInt J Geriatr Psychiatry200116990090611571771
   PubMed Web of Science ®Google Scholar
• OlinJTKatzIRMeyersBSSchneiderLSLebowitzBDProvisional diagnostic criteria for depression of Alzheimer disease: rationale and backgroundAm J Geriatr Psychiatry200210212914111925274
   PubMed Web of Science ®Google Scholar
• SinkKMHoldenKFYaffeKPharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidenceJAMA2005293559660815687315
   PubMed Web of Science ®Google Scholar
• GauthierSCummingsJBallardCManagement of behavioral problems in Alzheimer’s diseaseInt Psychogeriatr201022334637220096151
   PubMed Web of Science ®Google Scholar
• SchneiderLSDagermanKInselPSEfficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trialsAm J Geriatr Psychiatry200614319121016505124
   PubMed Web of Science ®Google Scholar
• GardetteVLapeyre-MestreMColeyNAntipsychotic use and mortality risk in community-dwelling Alzheimer’s disease patients: evidence for a role of dementia severityCurr Alzheimer Res2012991106111622950915
   PubMed Web of Science ®Google Scholar
• VigenCLMackWJKeefeRSCognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-ADAm J Psychiatry2011168883183921572163
   PubMed Web of Science ®Google Scholar
• LeePEGillSSFreedmanMBronskillSEHillmerMPRochonPAAtypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic reviewBMJ200432974577515194601
   PubMed Web of Science ®Google Scholar
• ParienteASanctussyDJMiremont-SalameGFactors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reportingCNS Drugs2010241556320030419
   PubMed Web of Science ®Google Scholar
• PereraGKhondokerMBroadbentMBreenGStewartRFactors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in LondonPLoS One2014911e10948425411838
   PubMed Web of Science ®Google Scholar
• WangPSSchneeweissSAvornJRisk of death in elderly users of conventional vs atypical antipsychotic medicationsN Engl J Med2005353222335234116319382
   PubMed Web of Science ®Google Scholar
• GillSSRochonPAHerrmannNAtypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort studyBMJ20053307489e445
   PubMed Web of Science ®Google Scholar
• DouglasIJSmeethLExposure to antipsychotics and risk of stroke: self-controlled case series studyBMJ2008337a122718755769
   PubMed Web of Science ®Google Scholar
• MaherARMaglioneMBagleySEfficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysisJAMA2011306121359136921954480
   PubMed Web of Science ®Google Scholar
• LiuMETsaiSJChangWCPopulation-based 5-year follow-up study in Taiwan of dementia and risk of strokePLoS One201384e6177123626726
   PubMed Web of Science ®Google Scholar
• TrifiròGVerhammeKMZiereGCaputiAPCh StrickerBHSturkenboomMCAll-cause mortality associated with atypical and typical antipsychotics in demented outpatientsPharmacoepidemiol Drug Saf200716553854417036366
   PubMed Web of Science ®Google Scholar
• YoungAAgeing and physiological functionsPhilos Trans R Soc Lond B Biol Sci19973521363183718439460068
   PubMed Web of Science ®Google Scholar
• MuhlbergWPlattDAge-dependent changes of the kidneys: Pharmacological implicationsGerontology199945524325310460985
   PubMed Web of Science ®Google Scholar
• FulopTJrWorumICsongorJFórisGLeoveyABody composition in elderly people: I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjectsGerontology19853116143972257
   PubMed Web of Science ®Google Scholar
• McLeanAJLe CouteurDGAging biology and geriatric clinical pharmacologyPharmacol Rev200456216318415169926
   PubMed Web of Science ®Google Scholar
• GinsbergGHattisDRussASonawaneBPharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individualsEnviron Health Perspect200511391243124916140636
   PubMed Web of Science ®Google Scholar
• Bentue-FerrerDTributOPolardEAllainHClinically significant drug interactions with cholinesterase inhibitors: a guide for neurologistsCNS Drugs2003171394796314533945
   PubMed Web of Science ®Google Scholar
• ZoliMMagalottiDBianchiGTotal and functional hepatic blood flow decrease in parallel with ageingAge Ageing1999281293310203201
   PubMed Web of Science ®Google Scholar
• WynneHACopeLHMutchERawlinsMDWoodhouseKWJamesOFThe effect of age upon liver volume and apparent liver blood flow in healthy manHepatology1989922973012643548
   PubMed Web of Science ®Google Scholar
• FliserDZeierMNowackRRitzERenal functional reserve in healthy elderly subjectsJ Am Soc Nephrol199337137113778439649
   PubMed Web of Science ®Google Scholar
• TrifiròGSpinaEAge-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systemsCurr Drug Metab201112761162021495972
   PubMed Web of Science ®Google Scholar
• MangoniAAJacksonSHAge-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applicationsBr J Clin Pharmacol200457161414678335
   PubMed Web of Science ®Google Scholar
• KruseWHProblems and pitfalls in the use of benzodiazepines in the elderlyDrug Saf1990553283342222867
   PubMed Web of Science ®Google Scholar
• SwiftCGEwenJMClarkePStevensonIHResponsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrationsBr J Clin Pharmacol19852021111183929807
   PubMed Web of Science ®Google Scholar
• ReidenbergMMLevyMWarnerHRelationship between diazepam dose, plasma level, age, and central nervous system depressionClin Pharmacol Ther1978234371374630787
   PubMed Web of Science ®Google Scholar
• CastledenCMGeorgeCFMarcerDHallettCIncreased sensitivity to nitrazepam in old ageBr Med J1977160521012318894
   PubMed Web of Science ®Google Scholar
• GreenblattDJDivollMHarmatzJSMacLaughlinDSShaderRIKinetics and clinical effects of flurazepam in young and elderly non-insomniacsClin Pharmacol Ther19813044754867285482
   PubMed Web of Science ®Google Scholar
• CummingsJLAlzheimer’s diseaseN Engl J Med20043511566715229308
   PubMed Web of Science ®Google Scholar
• ArcherHAEdisonPBrooksDJAmyloid load and cerebral atrophy in Alzheimer’s disease: an 11C-PIB positron emission tomography studyAnn Neurol200660114514716802294
   PubMed Web of Science ®Google Scholar
• WestMJKawasCHStewartWFRudowGLTroncosoJCHippocampal neurons in pre-clinical Alzheimer’s diseaseNeurobiol Aging20042591205121215312966
   PubMed Web of Science ®Google Scholar
• MorrisonJHHofPRLife and death of neurons in the aging brainScience199727853374124199334292
   PubMed Web of Science ®Google Scholar
• MorrisonJHHofPRSelective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer’s diseaseProg Brain Res200213646748612143403
   PubMed Web of Science ®Google Scholar
• HofPRBussièreTGoldGStereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer diseaseJ Neuropathol Exp Neurol2003621556712528818
   PubMed Web of Science ®Google Scholar
• CummingsJLBackCThe cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s diseaseAm J Geriatr Psychiatry199862 Suppl 16478
   PubMed Web of Science ®Google Scholar
• MufsonEJCountsSEPerezSEGinsbergSDCholinergic system during the progression of Alzheimer’s disease: therapeutic implicationsExpert Rev Neurother20088111703171818986241
   PubMedGoogle Scholar
• RainaPSantaguidaPIsmailaAEffectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guidelineAnn Intern Med2008148537939718316756
   PubMed Web of Science ®Google Scholar
• HowardRMcShaneRLindesayJDonepezil and memantine for moderate-to-severe Alzheimer’s diseaseN Engl J Med20123661089390322397651
   PubMed Web of Science ®Google Scholar
• SpinaEScordoMGD’ArrigoCMetabolic drug interactions with new psychotropic agentsFundam Clin Pharmacol200317551753814703714
   PubMed Web of Science ®Google Scholar
• SweeneyBPBromilowJLiver enzyme induction and inhibition: implications for anaesthesiaAnaesthesia200661215917716430569
   PubMed Web of Science ®Google Scholar
• TiseoPJPerdomoCAFriedhoffLTConcurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple dosesBr J Clin Pharmacol199846Suppl 130349839763
   PubMed Web of Science ®Google Scholar
• NagyCFKumarDPerdomoCAWasonSCullenEIPrattRDConcurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral dosesBr J Clin Pharmacol200458Suppl 1253315496220
   PubMed Web of Science ®Google Scholar
• HuangFFuYA review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, in healthy subjects and patientsCurr Clin Pharmacol20105211512420156150
   PubMedGoogle Scholar
• PiotrovskyVVan PeerAVan OsselaerNArmstrongMAerssensJGalantamine population pharmacokinetics in patients with Alzheimer’s disease: modeling and simulationsJ Clin Pharmacol200343551452312751272
   PubMed Web of Science ®Google Scholar
• GrossbergGTStahelinHBMessinaJCAnandRVeachJLack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medicationsInt J Geriatr Psychiatry200015324224710713582
   PubMed Web of Science ®Google Scholar
• WesemannWSonntagK-HMajJOn the pharmacodynamics and pharmacokinetics of memantineDrug Res198333811221134
   PubMed Web of Science ®Google Scholar
• RoySDHawesEMMidhaKKInfluence of urinary pH on the disposition of methoxyphenamine and three metabolites in humansJ Pharm Sci19877664274323625484
   PubMed Web of Science ®Google Scholar
• FreudenthalerSMeinekeISchreebKHBoakyeEGundert-RemyUGleiterCHInfluence of urine pH and urinary flow on the renal excretion of memantineBr J Clin Pharmacol19984665415469862242
   PubMed Web of Science ®Google Scholar
• European Medicine AgencyEbixa Tablets SPC, Summary of Product CharacteristicsEuropean Medicine Agency (EMA) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000463/WC500058763.pdfAccessed August 15, 2015
   Google Scholar
• HiemkeCPfuhlmannBInteractions and monitoring of antipsychotic drugsHandb Exp Pharmacol201221224126523129335
   PubMedGoogle Scholar
• CastbergISkogvollESpigsetOQuetiapine and drug interactions: evidence from a routine therapeutic drug monitoring serviceJ Clin Psychiatry200768101540154517960969
   PubMed Web of Science ®Google Scholar
• Nickl-JockschatTPaulzenMSchneiderFGrozingerMDrug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepineClin Neuropharmacol20093215519471186
   PubMed Web of Science ®Google Scholar
• WhitehousePJPriceDLStrubleRGClarkAWCoyleJTDelonMRAlzheimer’s disease and senile dementia: loss of neurons in the basal forebrainScience19822154537123712397058341
   PubMed Web of Science ®Google Scholar
• RoeCMAndersonMJSpivackBUse of anticholinergic medications by older adults with dementiaJ Am Geriatr Soc200250583684212028169
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society 2012 Beers Criteria Update Expert PanelAmerican Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adultsJ Am Geriatr Soc201260461663122376048
   PubMed Web of Science ®Google Scholar
• ShepherdGKlein-SchwartzWEdwardsRDonepezil overdose: A tenfold dosing errorAnn Pharmacother199933781281510466911
   PubMed Web of Science ®Google Scholar
• RöslerMAnandRCicin-SainAEfficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomised controlled trialBMJ1999318718463363810066203
   PubMed Web of Science ®Google Scholar
• Corey-BloomJAnandRVeachJA randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt J Ger Psychopharmacol199815565
   Google Scholar
• TariotPNSolomonPRMorrisJCA 5-month, randomized, placebocontrolled trial of galantamine in ADNeurology200054122269227610881251
   PubMed Web of Science ®Google Scholar
• CarnahanRMLundBCPerryPJChriscillesEAThe concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?J Am Geriatr Soc200452122082208715571547
   PubMed Web of Science ®Google Scholar
• RobinsonMRowettDLevertonAMabbottVChanges in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitorsPharmacoepidemiol Drug Saf200918865966419548222
   PubMed Web of Science ®Google Scholar
• TavassoliNSommetALapeyre-MestreMBagheriHMontrastrucJLDrug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary)Drug Saf200730111063107117973542
   PubMed Web of Science ®Google Scholar
• MasudaYCardiac effect of cholinesterase inhibitors used in Alzheimer’s disease – from basic research to bedsideCurr Alzheimer Res20041431532115975060
   PubMedGoogle Scholar
• MorganrothJGrahamSHartmanRAnandRElectrocardiographic effects of rivastigmineJ Clin Pharmacol200242555856812017350
   PubMed Web of Science ®Google Scholar
• BordierPGarrigueSBaroldSSBressollesNLanusseSClémentyJSignificance of syncope in patients with Alzheimer’s disease treated with cholinesterase inhibitorsEuropace20035542943114753643
   PubMed Web of Science ®Google Scholar
• BordierPGarrigueSLanusseSCardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer’s diseaseCNS Drugs200620541141716696580
   PubMed Web of Science ®Google Scholar
• KayrakMYaziciMAyhanSSKocFUlgenMSComplete atrioventricular block associated with rivastigmine therapyAm J Health Syst Pharm200865111051105318499878
   PubMed Web of Science ®Google Scholar
• PaulisonBLéosCLPotential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literatureCardiovasc Toxicol201010430631020865460
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationDeaths with Antipsychotics in Elderly Patients with Behavioral DisturbancesUS Food and Drug Administration2005 Available from: http://www.cchrint.org/pdfs/US_Food_and_Drug_Administration_Warnings_on_Antipsychotic_Drugs.pdfAccessed August 15, 2015
   Google Scholar
• ParienteAFourrier-RéglatADucruetTAntipsychotic use and myocardial infarction in older patients with treated dementiaArch Intern Med2012172864865322450214
   PubMedGoogle Scholar
• PrattNRougheadEESalterARyanPChoice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic reviewBMC Med Res Methodol2012127222682666
   PubMed Web of Science ®Google Scholar
• BallardCWaiteJThe effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s diseaseCochrane Database Syst Rev20061CD00347616437455
   PubMed Web of Science ®Google Scholar
• De DeynPPKatzIRBrodatyHLyonsBGreenspanABurnsAManagement of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidoneClin Neurol Neurosurg2005107649750815922506
   PubMed Web of Science ®Google Scholar
• SchneiderLSTariotPNDagermanKSEffectiveness of atypical antipsychotic drugs in patients with Alzheimer’s diseaseN Engl J Med2006355151525153817035647
   PubMed Web of Science ®Google Scholar
• HerrmannNLanctotKLDo atypical antipsychotics cause stroke?CNS Drugs20051929110315697324
   PubMed Web of Science ®Google Scholar
• Van NoordCEijgelsheimMStrickerBHDrug- and non-drug-associated QT interval prolongationBr J Clin Pharmacol2010701162320642543
   PubMed Web of Science ®Google Scholar
• Wenzel-SeifertKWittmannMHaenEQTc prolongation by psychotropic drugs and the risk of Torsade de PointesDtsch Arztebl In201110841687693
   Google Scholar
• BresslerRGrapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugsGeriatrics20066111121817112309
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
   PubMed Web of Science ®Google Scholar
• ZhouSFXueCCYuXQLiCWangGClinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoringTher Drug Monit200729668771018043468
   PubMed Web of Science ®Google Scholar